These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32939993)

  • 21. Introduction to the role of the immune system in melanoma.
    Margolin K
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):537-58. PubMed ID: 24880946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
    Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
    Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innate Immune Cells in Melanoma: Implications for Immunotherapy.
    Trocchia M; Ventrici A; Modestino L; Cristinziano L; Ferrara AL; Palestra F; Loffredo S; Capone M; Madonna G; Romanelli M; Ascierto PA; Galdiero MR
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
    Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
    Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming Immune Evasion in Melanoma.
    Eddy K; Chen S
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
    Berger TG; Haendle I; Schrama D; Lüftl M; Bauer N; Pedersen LØ; Schuler-Thurner B; Hohenberger W; Straten Pt Pt; Schuler G; Becker JC
    Int J Cancer; 2004 Aug; 111(2):229-37. PubMed ID: 15197776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
    Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C
    Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New avenues for melanoma immunotherapy: Natural Killer cells?
    Cristiani CM; Garofalo C; Passacatini LC; Carbone E
    Scand J Immunol; 2020 Apr; 91(4):e12861. PubMed ID: 31879979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment.
    Camisaschi C; Vallacchi V; Castelli C; Rivoltini L; Rodolfo M
    Expert Rev Mol Diagn; 2014 Jul; 14(6):643-6. PubMed ID: 24914691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
    Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.
    Oglesby A; Algazi AP; Daud AI
    Am J Clin Dermatol; 2019 Dec; 20(6):781-796. PubMed ID: 31228012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapy.
    Niveau C; Sosa Cuevas E; Saas P; Aspord C
    Immunology; 2024 Sep; 173(1):33-52. PubMed ID: 38742251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanoma as a model tumour for immuno-oncology.
    Maio M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii10-4. PubMed ID: 22918922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting tumour metabolism in melanoma to enhance response to immune checkpoint inhibition: A balancing act.
    Tiersma JF; Evers B; Bakker BM; Reijngoud DJ; de Bruyn M; de Jong S; Jalving M
    Cancer Treat Rev; 2024 Sep; 129():102802. PubMed ID: 39029155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.
    Jin P; Civini S; Zhao Y; De Giorgi V; Ren J; Sabatino M; Jin J; Wang H; Bedognetti D; Marincola F; Stroncek D
    Br J Cancer; 2014 Jun; 110(12):2955-64. PubMed ID: 24809778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes.
    Grotz TE; Vaince F; Hieken TJ
    Melanoma Res; 2013 Apr; 23(2):132-7. PubMed ID: 23344159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
    J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
    Jespersen H; Lindberg MF; Donia M; Söderberg EMV; Andersen R; Keller U; Ny L; Svane IM; Nilsson LM; Nilsson JA
    Nat Commun; 2017 Sep; 8(1):707. PubMed ID: 28955032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.